24/7 Market News Snapshot 25 September, 2025 – Leap Therapeutics, Inc. Common Stock (NASDAQ:LPTX)

September 25, 2025

DENVER, Colo., 25 September, 2025 (www.247marketnews.com) – (Nasdaq:LPTX) are discussed in this article.
Leap Therapeutics, Inc. (Nasdaq:LPTX) is experiencing significant trading activity, currently advancing to $0.363, marking an 18.13% increase from the previous close of $0.307. With a trading volume of 5.08 million shares, this strong upward momentum reflects positive investor sentiment and suggests heightened market interest, indicative of potential volatility. Investors are encouraged to monitor key support and resistance levels carefully and to consider implementing stop-loss strategies to mitigate risk as the stock shows bullish patterns.

In parallel, Leap Therapeutics is preparing to present the final clinical results from Part B of the DeFianCe study (NCT05480306) at the upcoming European Society for Medical Oncology (ESMO) Congress 2025. This Phase 2 study investigates the combination of sirexatamab (DKN-01), an innovative anti-DKK1 monoclonal antibody, with bevacizumab and chemotherapy for patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have previously received systemic therapy.

The findings will be disclosed during a Mini Oral Session focused on advancements in gastrointestinal cancer treatment scheduled for October 19, 2025. Renowned expert Zev A. Wainberg, M.D., will present the results, furthering the understanding of potential therapeutic strategies in this challenging patient population.

As Leap Therapeutics progresses, its commitment to developing targeted and immuno-oncology therapeutics remains steadfast. The firm looks forward to contributing valuable insights that may enhance treatment protocols for advanced MSS colorectal cancer, significantly impacting patient outcomes. This dual focus on trading performance and groundbreaking clinical research underscores Leap Therapeutics’ role as a vital player in the biotechnology sector, dedicated to addressing critical medical needs.

Related news for (LPTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.